Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albinterferon alfa 2b · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| alb-interferon arm 1 | EXPERIMENTAL | - |
| alb-interferon arm 2 | EXPERIMENTAL | - |
| alb-interferon arm 3 | EXPERIMENTAL | - |
| alb-interferon arm 4 | EXPERIMENTAL | - |
| peg-interferon | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Open-label treatment with albinterferon alfa 2b escalating single dose |
| Name | Type | Description |
|---|---|---|
| alb-interferon alfa 2b | DRUG | 900 mcg every 4 weeks |
| peg-interferon | DRUG | Peg-interferon alfa 2a: 180 mcg 1x per wk. |
| Albinterferon alfa 2b | BIOLOGICAL | recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0 |
Inclusion Criteria: * Age of 18 years or older * Clinical diagnosis of chronic hepatitis C * Infection with HCV genotype 2 or 3 * No previous IFNα-based therapy Exclusion Criteria: * Women of child-bearing potential if not using double barrier method of contraception, pregnant or nursing * Fertil...
Albinterferon alfa 2b is an investigational drug being developed for the treatment of Chronic Hepatitis C. It is a monoclonal antibody designed to target the condition, and it is currently in Phase 2 clinical development. The drug is not yet approved and remains under investigation for this infectious disease indication.
Albinterferon alfa 2b targets Chronic Hepatitis C, a viral infection of the liver. As a monoclonal antibody, it is designed to interfere with the disease process. The drug is being studied to evaluate its safety and efficacy in patients with this condition, though its specific molecular target is not detailed.
Albinterferon alfa 2b is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's potential as a treatment for Chronic Hepatitis C.
Albinterferon alfa 2b is currently in Phase 2 clinical development for Chronic Hepatitis C. It has completed two clinical trials, including a Phase 1 study and a Phase 2 study, with a total enrollment of 555 participants. The drug remains investigational and has not been approved by regulatory authorities.
Albinterferon alfa 2b has been studied in two completed clinical trials. The first, NCT00724776, was a Phase 1 single-dose study in Japanese patients with Chronic Hepatitis C, enrolling 30 participants. The second, NCT00759200, was a Phase 2 safety and efficacy study of the drug administered every 4 weeks in genotype 2/3 hepatitis C patients, enrolling 525 participants across multiple countries.
Albinterferon alfa 2b is also referred to as albumin interferon, as indicated by the title of one of its clinical trials, which studied the safety and efficacy of albumin interferon administered every 4 weeks. The drug is a single agent being developed by Novartis AG for Chronic Hepatitis C.